Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Eitemau Tebyg

• Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
  gan: Kondo, Shunsuke, et al.
  Cyhoeddwyd: (2020)
• A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
  gan: Doi, Toshihiko, et al.
  Cyhoeddwyd: (2020)
• Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
  gan: Zauderer, Marjorie G., et al.
  Cyhoeddwyd: (2021)
• Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines
  gan: Wu, Chung-Pu, et al.
  Cyhoeddwyd: (2020)
• A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
  gan: Yoh, Kiyotaka, et al.
  Cyhoeddwyd: (2016)